Anti-PDLIM7 antibody produced in rabbit

The gene PDLIM7 (PDZ and LIM domain protein-7) is mapped to human chromosome 5q35.3. It belongs to PDLIM family. PDLIM7 has PDZ (Discs-large homologous regions) domain and LIM (Lin11, Isl-1 & Mec-3) domains. PDLIM7 is expressed ubiquitously in human tissues, including leukocytes, spleen, lung, placenta, fetal liver, skeletal muscle, bone marrow and heart. PDLIM7 is also called as LMP1 (LIM mineralization protein).

PDZ and LIM domain protein 7 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Human PDZ and LIM domain protein-7 (PDLIM7) induces bone formation upon overexpression in fetal rat calvarial osteoblast cultures. PDLIM7 binds CBLC (E3 ubiquitin-protein ligase) and blocks CBLC-mediated degradation of receptor tyrosine kinase RETMEN2A, thereby enhancing ERK (Extracellular signal-regulated kinase) activation via RETMEN2A. Similarly, PDLIM7 binds with SMURF1 (Smad ubiquitin regulatory factor 1) and blocks ubiquitination of Smads (Mothers against decapentaplegic homolog), thus causing potentiation of bone morphogenetic protein activity. PDLIM7 is down-regulated in osteosarcoma tissues. Presence of PDLIM7 suppresses cell proliferation and invasion.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST74510

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.